Charles River Lifts Profit Forecast on Biotech Demand Rebound
CRL sits 75% above its 52-week low of $144.26.
Summary
Charles River beat Q2 estimates and raised its full-year profit outlook, signaling a genuine recovery in biotech spending. Revenue hit $1 billion vs. the $975.7 million consensus, and adjusted EPS of $3.02 trounced the $2.74 estimate. The company now sees 2026 adjusted EPS of $11.15-$11.45, up from $10.80-$11.30, driven by improving demand in its Discovery and Safety Assessment segment and better Manufacturing performance. This follows a Q1 net loss tied to divestitures, making the organic demand rebound the key takeaway. The stock is already near a 52-week high, so the guidance raise validates the recent run.
At the time of this announcement, CRL was trading at $253.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.3B. The 52-week trading range was $144.26 to $242.73. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.